Product Name: Human oxLDL Antibody (Okayama U. patent anti-oxLDL, Research Use)
Catalog Number: NBR-0761
Target Name: oxLDL
Trade Name: Okayama U. patent anti-oxLDL
Antibody Drug Description: The drug is a recombinant fully human anti-oxLDL monoclonal antibody, being developed by Okayama U. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: OLR1
Synonyms: CLEC8A; LOX-1; SCARE1
Target Description: Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis.
Ensembl:  ENSG00000173391
Uniprot:  P78380